Point Biopharma Global Inc Reports Results For The Quarter Ended In December: Earnings Summary

POINT Biopharma Global

25/03/2022 14:09

* POINT Biopharma Global Inc  PNT.OQ  reported a quarterly
adjusted loss of 16 cents​​ per share for the quarter ended in
December. The mean expectation of four analysts for the quarter
was for a loss of 23 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * POINT Biopharma Global Inc's reported EPS for the quarter
was a
loss of 16 cents​.
    * The mean earnings estimate of analysts had risen by
about 0.7%
in the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * POINT Biopharma Global Inc shares had risen by 18.8% this
quarter.
    * The company reported a quarterly loss of $14.2 million.
    * Wall Street's median 12-month price target for POINT
Biopharma
Global Inc is $17.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated March 25 at 02:09 p.m.  ​All
figures in US dollars unless otherwise stated